第16版日本《胃癌处理规约》更新及临床意义

胡祥

中国实用外科杂志 ›› 2026, Vol. 46 ›› Issue (4) : 463-468.

PDF(2369 KB)
PDF(2369 KB)
中国实用外科杂志 ›› 2026, Vol. 46 ›› Issue (4) : 463-468. DOI: 10.19538/j.cjps.issn1005-2208.2026.04.13
国际外科最新动态

第16版日本《胃癌处理规约》更新及临床意义

作者信息 +

Update and clinical significance of the 16th edition of Japanese Classification of Gastric Carcinoma

Author information +
文章历史 +

摘要

2026年3月4~6日,第98届日本胃癌学会(JGCA)年会在日本冲绳召开,同时发布了第16版《胃癌处理规约》(以下简称规约)。第16版规约修订较多,其保持了与第15版规约和第12版《食管癌处理规约》的一致性、连续性,维系与TNM分期接轨,补充了新的规定。第16版规约主要修订了食管胃结合部癌相关内容、胃癌进展度分期、癌肿状态的记载方法和治疗结果的评价方法。

Abstract

From March 4 to 6,2026,the 98th Annual Meeting of the Japanese Gastric Cancer Association (JGCA) was held in Okinawa, Japan, where the 16th edition of the Japanese Classification of Gastric Carcinoma (hereinafter referred to as the Classification) was also released. This edition has undergone significant modifications, maintaining consistency and continuity with the 15th edition of the “Classification of Gastric Carcinoma” and the 12th edition of the “Classification of Esophageal cancer”, aligning with the TNM classification of the UICC/AJCC, and incorporating new provisions. The 16th edition of the “Classification of Gastric Carcinoma” primarily revises the methods for recording the cancer at the gastroesophageal junction, the staging of gastric cancer progression, the state of the cancer, and the evaluation methods for treatment outcomes.

关键词

胃癌 / 食管胃结合部癌 / 进展度分期 / 胃癌处理规约 / 食管癌处理规约

Key words

gastric carcinoma / esophagogastric junction carcinoma / progressive staging / classification of gastric carcinoma / classification of esophageal cancer

引用本文

导出引用
胡祥. 第16版日本《胃癌处理规约》更新及临床意义[J]. 中国实用外科杂志. 2026, 46(4): 463-468 https://doi.org/10.19538/j.cjps.issn1005-2208.2026.04.13
HU Xiang. Update and clinical significance of the 16th edition of Japanese Classification of Gastric Carcinoma[J]. Chinese Journal of Practical Surgery. 2026, 46(4): 463-468 https://doi.org/10.19538/j.cjps.issn1005-2208.2026.04.13
中图分类号: R6   

参考文献

[1]
日本胃癌学会. 胃癌取り扱い規約[M]. 1版. 東京: 金原出版株式会社, 1962.
[2]
日本胃癌学会. 胃癌取り扱い規約[M]. 15版. 東京: 金原出版株式会社, 2017.
[3]
日本胃癌学会. 胃癌取り扱い規約[M]. 16版. 東京: 金原出版株式会社, 2026.
[4]
日本胃癌学会. 胃癌治療ガイドライン[M]. 1版. 東京: 金原出版株式会社, 2001.
[5]
日本食道学会. 食道癌取り扱い規約[M]. 12版. 東京: 金原出版株式会社, 2022.
[6]
World Health Organization. ICD-11 for Mortality and Morbidity Statistitics[EB/OL].(2026-01)[2026-03-11]. https://icd.who.int/browse/2026-01/mms/en.
[7]
Fritz A. 国际疾病分类肿瘤学专辑(ICD-O)[M]. 董景五,译. 3版. 北京: 人民卫生出版社.
[8]
Bosman F, Carneiro F, Hruban R, et al. WHO classification of tumors of the digestive system[M]. 4th ed. Lyon: IARC Press, 2010.
[9]
WHO Classification of Tumours Editorial Board. WHO classification of tumours. Digestive system tumours[M]. 5th ed. Lyon: IARC Press, 2019.
[10]
菅野健太郎. 胃食道接合部の定義の新展开.京都国際コンセンサス会議の経緯と結果[J]. 消化器内視鏡, 2020, 32: 637-645.
[11]
西満正, 加治佐隆, 阿久根務,など. 噴門部周辺の外科噴門癌について─食道胃境界部癌の提唱[J]. 外科治療, 1973, 15: 1328-1338.
[12]
Siewert JR, Holscher AHH, Becker K, et al. Kardiacarcinoma : Versuch einer therapeutisch relevanten Klassifikation[J]. Chirurg, 1987, 58: 25-32. PMID: 3829805.
[13]
瀬戸泰之, 山下裕玄. 食道胃接合部の诊断と治疗[J]. 日消誌, 2015, 112: 1769-1775.
[14]
日本胃癌学会. 胃癌取り扱い規約[M]. 11版. 東京: 金原出版株式会社, 1985.
[15]
日本胃癌学会. 胃癌取り扱い規約[M]. 12版. 東京: 金原出版株式会社, 1993.
[16]
日本胃癌学会. 胃癌取り扱い規約[M]. 13版. 東京: 金原出版株式会社, 1999.
[17]
日本胃癌学会. 胃癌取り扱い規約[M]. 14版. 東京: 金原出版株式会社, 2010.
[18]
日本食道学会. 食道癌取り扱い規約[M]. 2版. 東京: 金原出版株式会社, 1972.
[19]
日本食道学会. 食道癌取り扱い規約[M]. 8版. 東京: 金原出版株式会社, 1992.
[20]
日本食道学会. 食道癌取り扱い規約[M]. 10版. 東京: 金原出版株式会社, 2007.
[21]
日本食道学会. 食道癌取り扱い規約[M]. 11版. 東京: 金原出版株式会社, 2015.
[22]
Brieriey JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours[M]. 8th ed. New York: Wiley-Blackwell, 2017.
[23]
大森宏辛, 小柳和夫, 藤田武郎,など. 食道胃接合部腺癌に対するmultimodal minimally invasive extended surgery[J]. 消化器外科, 2018, 41: 159-165.
[24]
Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: A prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1):120-127. DOI: 10.1097/SLA.0000000000003499.
[25]
日本胃癌学会. 胃癌治療ガイドライン[M]. 7版. 東京: 金原出版株式会社, 2025.
[26]
Kurokawa Y, Takeuchi H, Doki Y, et al. Establishing a standard surgery for esophagogastric junction cancer: Final results from the JGCA-JES nationwide prospective study[J]. Cell Rep Med, 2026, 7(2): 102627. DOI: 10.1016/j.xcrm.2026.102627.
[27]
日本胃癌学会. 胃癌治療ガイドライン[M]. 6版. 東京: 金原出版株式会社, 2021.
[28]
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer : ESMO Clinical Practice Guideline for diagnosis,treatment and follow-up[J]. Ann Oncol, 2022, 33(10): 1005-1020. DOI: 10.1016/j.annonc.2022.07.004.
[29]
AI-Batran S, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patiens with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 trial[J]. JAMA Oncol, 2017, 3(9):1237-1244. DOI: 10.1001/jamaoncol.2017.0515.
[30]
Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6): 653-660. DOI: 10.1002/bjs.9484.

脚注

利益冲突 作者声明不存在利益冲突


PDF(2369 KB)

Accesses

Citation

Detail

段落导航
相关文章

/